Clinical Trial

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This multicenter phase 1 trial with "3 + 3" dose escalation design seeks to examine the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of chimeric antigen receptors targeting the B cell surface antigens CD19/20/22 following administration of a chemotherapy lymphodepletion regimen in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) or Non-Hodgkin's lymphoma (NHL). The overall goals of this study are to estimate maximum tolerated dose (MTD) level, establish the overall safety profile and evaluate initial efficacy of administering duo-CAR-T cell treatment in this patient population.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-10; most recent amendment 2026-05-11.
Status change: Not Yet Recruiting → Recruiting 2025-04-03
Trial Details
NCT Number NCT06879340
Lead Sponsor University of Kansas Medical Center
Conditions B-Cell Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
Enrollment 54 participants
Start Date 2025-03-31
Primary Completion 2030-03 (estimated)
Study Completion 2040-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-14